for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Arcturus Therapeutics Holdings Inc

ARCT.O

Latest Trade

43.19USD

Change

-2.35(-5.16%)

Volume

1,495,413

Today's Range

39.13

 - 

47.21

52 Week Range

8.51

 - 

129.71

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
45.54
Open
47.21
Volume
1,495,413
3M AVG Volume
39.67
Today's High
47.21
Today's Low
39.13
52 Week High
129.71
52 Week Low
8.51
Shares Out (MIL)
26.28
Market Cap (MIL)
1,135.05
Forward P/E
-11.78
Dividend (Yield %)
--

Next Event

Arcturus Therapeutics Holdings Inc at Barclays Global Healthcare Conference (Virtual)

Latest Developments

More

Arcturus Therapeutics Posts Q4 Loss Per Share Of $1.25

Arcturus Therapeutics Acquires Exclusive License To Mrna Manufacturing Technology From Alexion Pharmaceuticals

Arcturus Therapeutics Holdings Inc Says Anticipate Interim Phase 2 Data In Early 2021

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines and vaccines company. The Company’s technologies include LUNAR lipid-mediated delivery, STARR mRNA Technology and mRNA drug substance along with drug product manufacturing. Its pipeline of ribonucleic acid (RNA) therapeutic candidates include programs to treat ornithine transcarbamylase (OTC) deficiency, cystic fibrosis, glycogen storage disease type three, hepatitis B, non-alcoholic steatohepatitis (NASH) and a self-replicating mRNA vaccine for severe acute respiratory syndrome coronavirus two (SARS-CoV-2). Its RNA therapeutics platforms have applications in types of nucleic acid medicines, including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, deoxyribonucleic acid (DNA) and gene editing therapeutics. The Company is focused on liver and respiratory diseases.

Industry

Biotechnology & Drugs

Contact Info

10628 Science Center Dr Ste 250

SAN DIEGO, CA

92121-1132

United States

+1.858.9002660

https://arcturusrx.com/

Executive Leadership

Peter C. Farrell

Independent Chairman of the Board

Joseph E. Payne

President, Chief Executive Officer, Director

Andrew H. Sassine

Chief Financial Officer, Director

Padmanabh Chivukula

Chief Operating Officer, Chief Scientific Officer

Steven Hughes

Chief Development Officer

Key Stats

2.38 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.1K
EPS (USD)

2018

-2.130

2019

-2.150

2020

-3.550

2021(E)

-3.263
Price To Earnings (TTM)
--
Price To Sales (TTM)
118.99
Price To Book (MRQ)
2.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
3.81
LT Debt To Equity (MRQ)
3.49
Return on Investment (TTM)
-29.58
Return on Equity (TTM)
-25.83

Latest News

Latest News

Philippines can secure up to 25 million doses of Moderna, Arcturus vaccines-ambassador

The Philippines will be able to secure between four to 25 million doses of COVID-19 vaccines from Moderna Inc and Arcturus Therapeutics Holdings Inc, the Southeast Asia country's ambassador to Washington said on Friday.

Philippines can secure up to 25 mln doses of Moderna, Arcturus vaccines-ambassador

The Philippines will be able to secure between four to 25 million doses of COVID-19 vaccines from Moderna Inc and Arcturus Therapeutics Holdings Inc , the Southeast Asia country's ambassador to Washington said on Friday.

Arcturus expects its COVID-19 vaccine to be ready by first-quarter 2021

U.S. biotech firm Arcturus Therapeutics said it expects to start distributing its COVID-19 vaccine candidate in the first quarter of next year after early stage trials showed promising results.

Arcturus CEO says in talks with a dozen countries for COVID-19 vaccine supply deals

Arcturus Therapeutics Holdings Inc is in discussions with about a dozen countries for supply deals of its coronavirus vaccine that is currently in early human testing, the company's chief executive officer told Reuters on Thursday.

Arcturus Therapeutics begins human trials of potential COVID-19 vaccine

Arcturus Therapeutics Holdings Inc said on Tuesday the first group of participants had been dosed in an early-stage trial testing its COVID-19 vaccine candidate and that results from the trial were expected in the fourth quarter.

BRIEF-Arcturus Therapeutics To Be Added To Russell 2000® Index

* ARCTURUS THERAPEUTICS TO BE ADDED TO RUSSELL 2000® INDEX Source text for Eikon: Further company coverage:

Singapore scientists to start human trials of COVID-19 vaccine in August

Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics <ARCT.O> plan to start human trials in August after promising initial responses in mice.

BRIEF-Arcturus Therapeutics Announces First Healthy Volunteer Dosed In Phase 1 Study Of ARCT-810

* ARCTURUS THERAPEUTICS ANNOUNCES FIRST HEALTHY VOLUNTEER DOSED IN PHASE 1 STUDY OF ARCT-810 FOR ORNITHINE TRANSCARBAMYLASE (OTC) DEFICIENCY Source text for Eikon: Further company coverage:

CORRECTED-BRIEF-Arcturus Reports Positive Preclinical Data For Covid-19 Vaccine Candidate (April 27)

(Corrects company name in second bullet) Arcturus Therapeutics Holdings Inc:

BRIEF-Arcturus Therapeutics Announces Proposed Public Offering Of Common Stock

* ARCTURUS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

BRIEF-Arcturus Therapeutics Plans To Initiate A Human Clinical Trial This Summer For Its Covid-19 Vaccine

* ARCTURUS THERAPEUTICS ANNOUNCES CLINICAL TRIAL TIMELINE FOR ITS COVID-19 VACCINE

BRIEF-Arcturus Therapeutics Files Prospectus Supplement To Offer And Sell Up To $40 Million Of Common Stock - SEC Filing

* ARCTURUS THERAPEUTICS FILES PROSPECTUS SUPPLEMENT TO OFFER AND SELL UP TO $40 MILLION OF COMMON STOCK - SEC FILING Source : (https://bit.ly/2QMTMVq) Further company coverage:

BRIEF-Arcturus Therapeutics Reports Fourth Quarter And Year End 2019 Financial Results

* ARCTURUS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS

BRIEF-Arcturus Awarded S$14 MLN In Grants To Support Development Of Covid-19 Vaccine By Singapore Economic Development Board

* AWARDED S$14 MILLION (ABOUT US$10 MILLION) IN GRANTS TO SUPPORT DEVELOPMENT OF COVID-19 VACCINE BY SINGAPORE ECONOMIC DEVELOPMENT BOARD Source text for Eikon: (bit.ly/2TnTrKI) Further company coverage:

BRIEF-Arcturus Therapeutics And Duke-Nus Medical School Partner To Develop A Coronavirus Vaccine Using Starr Technology

* ARCTURUS THERAPEUTICS AND DUKE-NUS MEDICAL SCHOOL PARTNER TO DEVELOP A CORONAVIRUS (COVID-19) VACCINE USING STARR TECHNOLOGY™ Source text for Eikon: Further company coverage:

BRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeutics

* AMIR EFRATI - ON APRIL 27, SENT LETTER TO ISRAELI COURT SHOWING OPPOSITION TO TRANSACTION THEY BELIEVE ARCTURUS THERAPEUTICS BOARD HAS BEEN PURSUING

BRIEF-Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Payne

* JOSEPH PAYNE SAYS "REJECTS" ARCTURUS THERAPEUTICS' BOARD OF DIRECTORS' LATEST LAWSUIT AGAINST PAYNE

BRIEF-Arcturus Therapeutics Files Lawsuit Against Former CEO Joseph Payne And His Associates

* ARCTURUS THERAPEUTICS FILES LAWSUIT AGAINST JOSEPH E. PAYNE AND HIS ASSOCIATES FOR VIOLATIONS OF FEDERAL SECURITIES LAWS

BRIEF-Joseph Payne Sent Letter To Arcturus Board To Restate Prior Demand To Convene EGM

* JOSEPH E. PAYNE -ON APRIL 18, SENT LETTER TO ARCTURUS THERAPEUTICS LTD. BOARD TO RESTATE HIS PRIOR DEMAND TO CONVENE EGM OF SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2F05p2z) Further company coverage:

BRIEF-Joseph Payne Says Calling On Arcturus Therapeutics' Board To Hold EGM "Without Further Delay"

* JOSEPH PAYNE SAYS CALLING ON ARCTURUS THERAPEUTICS' BOARD TO HOLD ITS EXTRAORDINARY GENERAL MEETING "WITHOUT FURTHER DELAY"

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up